For hospital pharmacy directors at pediatric departments, emergency medicine physicians treating children with acute gastroenteritis, and procurement managers at children’s hospitals, a persistent clinical challenge remains: children are more vulnerable to dehydration and electrolyte disorders than adults due to higher body water content, immature renal function, and faster metabolic rates. Vomiting, diarrhea, high fever, surgery, and certain diseases can rapidly lead to hypovolemia, electrolyte imbalances (hyponatremia, hypokalemia), and metabolic acidosis. Standard adult IV fluids may not be appropriately formulated for pediatric patients (incorrect electrolyte concentrations, glucose levels). Pediatric electrolyte supplements injection directly resolves this challenge as an intravenous infusion preparation specially designed for children, containing appropriate amounts of electrolyte components (sodium, potassium, chloride, calcium, magnesium, glucose) to help maintain osmotic pressure, acid-base balance, and energy supply. According to the latest industry benchmark, the global market for Pediatric Electrolyte Supplements Injection was valued at USD 26.9 million in 2024 and is forecast to reach a readjusted size of USD 39.4 million by 2031, growing at a compound annual growth rate (CAGR) of 5.2% during the forecast period 2025-2031. This steady growth reflects consistent demand for pediatric IV fluids in hospital settings, driven by the high incidence of acute gastroenteritis in children, surgical procedures requiring perioperative fluid management, and neonatal intensive care unit (NICU) requirements.
*Global Leading Market Research Publisher QYResearch announces the release of its latest report “Pediatric Electrolyte Supplements Injection – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Pediatric Electrolyte Supplements Injection market, including market size, share, demand, industry development status, and forecasts for the next few years.*
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/4662303/pediatric-electrolyte-supplements-injection
1. Product Definition: Pediatric-Specific IV Fluids for Rehydration and Electrolyte Balance
Pediatric electrolyte supplements injection is an intravenous infusion preparation specially designed for children of different age groups (neonates, infants, toddlers, older children). It is primarily used to replenish and regulate lost water and electrolyte balance in the body caused by acute gastroenteritis (vomiting, diarrhea), high fever with insensible water loss, pre- and post-operative fluid management, burns, trauma, and certain metabolic or renal diseases. The formulation typically contains appropriate amounts of electrolyte components including sodium (Na⁺), potassium (K⁺), chloride (Cl⁻), calcium (Ca²⁺), magnesium (Mg²⁺), and glucose (dextrose) to help maintain the body’s osmotic pressure, acid-base balance, and provide a basic energy supply. Pediatric formulations differ from adult maintenance IV fluids in: (1) lower sodium concentration (risk of hypernatremia in infants with limited renal concentrating ability), (2) higher glucose concentration (children have higher glucose utilization rates and risk of hypoglycemia if fasting), (3) potassium content (adjusted for age-specific requirements), (4) osmolarity (avoiding hypertonic solutions that can cause phlebitis or fluid shifts). This injection is particularly effective in treating dehydration and electrolyte disorders caused by vomiting, diarrhea, high fever, surgery, or certain diseases (diabetic ketoacidosis, adrenal insufficiency, renal tubular disorders).
Two primary volume sizes (segment by type – QYResearch classification):
- 250ml: 9.375g Glucose and 0.5625g Sodium Chloride – Smaller volume, suitable for infants, toddlers, and smaller children. Glucose concentration 3.75% (37.5g/L), sodium chloride concentration 0.225% (2.25g/L) – a hypotonic or isotonic maintenance fluid depending on age. Estimated larger volume segment by unit count.
- 500ml: 18.75g Glucose and 1.125g Sodium Chloride – Larger volume, suitable for older children, adolescents, or cases requiring more substantial fluid resuscitation. Glucose concentration 3.75% (same as 250ml), sodium chloride concentration 0.225% (same). Lower cost per ml.
End-user segments (segment by application):
- Hospital – Largest segment (~70-75% of revenue). Used in pediatric wards, pediatric intensive care units (PICU), neonatal intensive care units (NICU), emergency departments, operating rooms (perioperative), and general pediatric inpatient units. Prescription required.
- Clinic – Moderate segment (~15-20%). Used in outpatient infusion centers, urgent care centers, and some primary care clinics with IV infusion capabilities.
- Other – Home healthcare (home IV therapy), long-term care facilities, rehabilitation centers (~5-10%).
2. Industry Development Trends: China-Centric Manufacturing, Niche Market, and Stable Demand
Based on analysis of corporate annual reports (limited, as most manufacturers are Chinese pharmaceutical companies), pediatric healthcare trends, and industry news from Q4 2025 to Q2 2026, four dominant trends shape the pediatric electrolyte supplements injection sector:
2.1 China-Centric Manufacturing with Limited Global Presence
The pediatric electrolyte supplements injection market is heavily concentrated in China. All eight manufacturers identified are Chinese pharmaceutical companies: Sichuan Kelun Pharmaceutical Co., Ltd. (one of China’s largest IV fluid manufacturers), Harbin Sanlian Pharmaceutical Co., Ltd., Anhui Fengyuan Pharmaceutical Co., Ltd., Shijiazhuang Siyao Co., Ltd. (part of CSPC Pharmaceutical Group), Jiangsu Hengrui Medicine Co., Ltd. (one of China’s largest pharmaceutical companies, primarily oncology and anesthesia, but includes IV fluids), Shanxi Nuocheng Pharmaceutical Co., Ltd., Shandong Hualu Pharmaceutical Co., Ltd., Shandong Kelun Pharmaceutical Co., Ltd. (subsidiary of Sichuan Kelun). The product is not widely approved or marketed outside China (US FDA, EMA, PMDA). This is a niche, regionally confined product. The market size (USD 26.9 million in 2024) reflects the specialized nature of pediatric-specific IV fluids (general purpose adult IV fluids have much larger markets).
2.2 Consolidation Among IV Fluid Manufacturers
The IV fluid manufacturing market in China has been consolidating. Sichuan Kelun Pharmaceutical is the dominant player in Chinese IV fluids (estimated 30-40% market share across all IV fluid types). Jiangsu Hengrui and CSPC (Shijiazhuang Siyao) are major pharmaceutical conglomerates. Smaller regional manufacturers (Shanxi Nuocheng, Anhui Fengyuan, Harbin Sanlian) compete on local relationships and price. Kelun’s multiple subsidiaries (including Shandong Kelun) expand its reach. For pediatric electrolyte supplements injection, Kelun and Hengrui likely hold the largest market shares.
2.3 Stable Demand Driven by Acute Gastroenteritis and Surgical Volumes
Demand for pediatric IV fluids is driven by: (1) acute gastroenteritis – a leading cause of pediatric hospitalization worldwide; rotavirus, norovirus, bacterial enteritis cause vomiting and diarrhea leading to dehydration; (2) pediatric surgical procedures – pre-operative fluid management, intraoperative maintenance, post-operative rehydration; (3) neonatal care – premature infants require careful fluid and electrolyte management; (4) febrile illnesses – high fever increases insensible water loss. These are non-cyclical, essential medical needs. The COVID-19 pandemic (2020-2023) caused some disruption (reduced pediatric hospitalizations due to lockdowns, but increased severity of delayed care). Post-pandemic, volumes have normalized.
2.4 Competition from General Adult IV Fluids (Off-Label Use)
In many settings, especially smaller hospitals and clinics in cost-sensitive environments, general adult IV fluids (e.g., 5% dextrose in 0.225% saline, 0.9% normal saline, Ringer’s lactate, Plasma-Lyte) are used off-label for pediatric patients. Physicians may adjust infusion rates, add potassium chloride separately, or accept non-optimal formulations. This off-label use competes with specialized pediatric electrolyte supplements injection. Pediatric-specific formulations offer the advantage of convenience (pre-mixed, age-appropriate concentrations) and reduced medication error risk (no need to calculate and add electrolytes). However, they are often more expensive per unit than adult IV fluids.
Industry Layering Perspective: Hospital vs. Clinic vs. Other
- Hospital – Largest segment. Pediatric formulations preferred due to safety and convenience. Hospital formularies include both pediatric-specific and general IV fluids.
- Clinic – Moderate segment. May use pediatric-specific for convenience or may substitute general IV fluids depending on cost and availability.
- Other – Home healthcare. Pediatric-specific may be used for children requiring long-term IV hydration (e.g., short bowel syndrome, intestinal failure).
3. Market Segmentation and Competitive Landscape
Segment by Volume Size (Type):
- 250ml – Larger volume segment by unit count (~55-60% of units, ~50-55% of revenue). Used for infants, toddlers, smaller children.
- 500ml – Larger volume segment by revenue (~40-45% of units, ~45-50% of revenue). Used for older children, adolescents, or multiple doses.
Segment by End-User (Application):
- Hospital – Largest (~70-75% of revenue)
- Clinic – Moderate (~15-20%)
- Other – Small (~5-10%)
Key Market Players (QYResearch-identified):
Sichuan Kelun Pharmaceutical Co., Ltd. – Dominant IV fluid manufacturer in China; produces pediatric electrolyte supplements injection under its brand. Shandong Kelun Pharmaceutical Co., Ltd. – Subsidiary of Sichuan Kelun. Jiangsu Hengrui Medicine Co., Ltd. – Major pharmaceutical company; IV fluids are a small part of portfolio but include pediatric formulations. Shijiazhuang Siyao Co., Ltd. (CSPC Pharmaceutical Group) – Another major player. Harbin Sanlian Pharmaceutical Co., Ltd. – Regional player (Northeast China). Anhui Fengyuan Pharmaceutical Co., Ltd. – Regional player. Shanxi Nuocheng Pharmaceutical Co., Ltd. – Regional player. Shandong Hualu Pharmaceutical Co., Ltd. – Regional player. The market is moderately concentrated, with Sichuan Kelun and Jiangsu Hengrui holding significant shares.
4. Exclusive Expert Insights and Recent Developments (Q4 2025 – Q2 2026)
Insight #1 – Pediatric Formulation Optimization and Evidence Updates
Guidelines for pediatric maintenance IV fluids have evolved. Historically, hypotonic solutions (0.2-0.225% saline) were recommended to avoid hypernatremia. However, evidence of hospital-acquired hyponatremia (due to ADH secretion in sick children) has led some guidelines (NICE, AAP 2018) to recommend isotonic solutions (0.9% saline with 5% dextrose) for maintenance in many pediatric patients. The formulations described (0.225% saline with 3.75% dextrose) are hypotonic. Manufacturers may need to introduce isotonic pediatric formulations to align with evolving guidelines. This represents a product development opportunity.
Insight #2 – Rotavirus Vaccination Impact on Demand
Rotavirus vaccination (introduced in China’s expanded immunization program in phases, not yet universal as of 2026) reduces the incidence of severe rotavirus gastroenteritis, a major cause of pediatric dehydration hospitalization. As vaccination coverage increases, the number of rotavirus-related hospitalizations decreases, potentially reducing demand for pediatric IV fluids. However, other causes of gastroenteritis (norovirus, bacterial, other viral) remain prevalent. The net impact on market growth is neutral to slightly negative.
Insight #3 – Plasticizer and DEHP Concerns in IV Bags
Traditional IV bags (PVC with DEHP plasticizer) have raised concerns about DEHP leaching into IV fluids, particularly for neonates and infants (reproductive toxicity concerns). Many pediatric hospitals prefer DEHP-free IV bags (non-PVC, or PVC with alternative plasticizers). Manufacturers producing pediatric electrolyte supplements injection in DEHP-free bags may have a competitive advantage. No information is provided in the source about bag composition.
Typical User Case (Q1 2026 – Pediatric Emergency Department, Tertiary Hospital):
A tertiary children’s hospital emergency department treats a 2-year-old male with acute viral gastroenteritis (vomiting x 12 hours, diarrhea x 24 hours, signs of moderate dehydration: dry mucous membranes, decreased urine output, tachycardia). The physician orders IV rehydration: 250ml pediatric electrolyte supplement injection (0.225% saline, 3.75% dextrose) infused over 4 hours (initial bolus, then maintenance). The child receives the IV fluids, vomiting subsides, urine output normalizes. After 6 hours of observation, the child is discharged home on oral rehydration solution. The hospital pharmacy dispenses the IV fluid from stock (procured from Sichuan Kelun at USD 1.20 per 250ml bag). This case is typical: moderate dehydration, pediatric-specific formulation used for convenience and age-appropriate electrolyte composition.
5. Technical Challenges and Future Pathways
Despite steady demand, challenges persist for pediatric electrolyte supplements injection market:
- Competition from oral rehydration therapy (ORT) – For mild-to-moderate dehydration, WHO-recommended oral rehydration solution (ORS) is highly effective, low-cost, avoids IV access, and can be administered at home. Many children with acute gastroenteritis can be managed with ORS alone, avoiding hospitalization and IV fluids. This reduces potential demand for pediatric IV fluids. Only severe dehydration (requiring IV access for rapid rehydration) or cases with persistent vomiting (inability to tolerate ORS) require IV therapy.
- IV access challenges in children – Establishing IV access in infants and young children is technically difficult (small veins, patient movement, distress). Pediatric IV fluids therefore require skilled pediatric nurses or physicians. In resource-limited settings, ORS may be preferred even for moderate dehydration to avoid difficult IV access.
- Product differentiation limited – Pediatric electrolyte supplement injection formulations are similar across manufacturers (standardized compositions, compliance with pharmacopoeia). Competition is primarily on price, manufacturing efficiency, and distribution relationships with hospital group purchasing organizations (GPOs), not on product innovation.
Future Direction: The pediatric electrolyte supplements injection market will continue its 5% CAGR through 2031, driven by: (1) stable incidence of acute gastroenteritis in children, (2) pediatric surgical volumes, (3) neonatal intensive care requirements, (4) continued preference for pediatric-specific formulations in hospitals. Key strategic imperatives for manufacturers: (1) align formulations with evolving evidence (consider isotonic options), (2) offer DEHP-free bag options for sensitive populations, (3) expand distribution through hospital GPO relationships, (4) maintain manufacturing efficiency to compete on price in a commodity-like market. For hospital pharmacy directors, pediatric electrolyte supplements injection offers a convenient, safe, pre-mixed option for pediatric rehydration, though oral rehydration therapy should be prioritized for mild-to-moderate dehydration when feasible.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
